Introduction
As part of our search for new lead compounds for the treatment of African trypanosomiasis (African sleeping sickness) and other parasitic infections, aromatic dicationic compounds, such as DB75 [2,5-bis(4-amidinophenyl) furan], have been evaluated for efficacy in multiple models of infection. These diamidine-type compounds are effective against a broad range of pathogens in vitro, including Trypanosoma brucei, Leishmania spp., Pneumocystis carinii and Plasmodium falciparum (Das and Boykin, 1977; Bell et al., 1990; Tidwell et al., 1990; Bell et al., 1993) . However, antiparasitic activity following oral administration of these compounds in rodents is poor (Steck et al., 1981; Boykin et al., 1996; Hall et al., 1998) , which is believed to be largely due to the positively charged cationic moieties that limit transcellular transport across the intestinal epithelium (Zhou et al., 2002) .
A prodrug of DB75, 2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime (DB289), exhibits enhanced oral efficacy and reduced acute toxicity in animal models of Pneumocystis pneumonia and African trypanosomiasis (Boykin et al., 1996; Fitzpatrick et al., 2004) . In clinical trials involving patients with primary stage African trypanosomiasis, treatment with oral DB289 (100 mg, twice daily for 10 days) achieved cure rates of approximately 95% (Dr.
Carol Olson, Immtech Pharmaceuticals Inc., personal communication). In clinical trials involving patients with Plasmodium vivax or acute, uncomplicated Plasmodium falciparum, treatment with oral DB289 (100 mg, twice daily for 5 days) achieved cure rates of 96% (Yeramian et al., 2005) . Oral DB289 was also well tolerated, with no serious side effects (Yeates, 2003) . DB289 has completed Phase II clinical trials for African trypanosomiasis in the Democratic Republic of Congo and Angola, for malaria in Thailand and for Pneumocystis pneumonia in Peru.
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7 As a prodrug, DB289 must be biotransformed to the active compound DB75 in sufficient quantities for effective treatment. The phase I metabolic pathway for the conversion of DB289 to DB75 has been studied in vitro with freshly isolated rat hepatocytes (Zhou et al., 2004) . This pathway consisted of sequential oxidative O-demethylation and reductive Ndehydroxylation reactions with four intermediate metabolites formed (Fig. 1) . Clinical trials in humans demonstrated oral DB289 to be well absorbed and efficiently converted to DB75.
However, pharmacokinetic studies have indicated that DB75 plasma concentrations are highly variable among patients (Yeramian et al., 2005) . Such variability could be due in part to interindividual differences in the extent of metabolic conversion of DB289 to DB75.
Therefore, to provide a more comprehensive understanding of DB289 in vivo, an in-depth in vitro study was undertaken to identify the enzymes responsible for the biotransformation of DB289 to DB75.
The reductive N-dehydroxylation reactions (conversion of M1 to M3, conversion of M2 to M4, and M4 conversion to DB75; Fig. 1 ) were recently shown to be catalyzed by cytochrome b 5 /NADH b 5 reductase, with no requirement for P450s (Saulter et al., 2005) .
However, little is known about the oxidative O-demethylation pathways of DB289. Accordingly, we have performed a reaction phenotyping study to identify the enzymes responsible for the first step in the conversion of DB289 to DB75, i.e., oxidative Odemethylation (M1 formation).
Our results suggest that the initial oxidative O-demethylation of DB289 is predominantly catalyzed by CYP4F enzymes in human liver microsomes. These findings not only advance our understanding of the metabolism of this new drug candidate, but, by DMD #10587 8 implicating CYP4F enzymes in the metabolism of a xenobiotic, they have important implications for reaction phenotyping in practice and human drug metabolism in general.
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Materials and Methods
Chemicals. DB289 was synthesized by Medichem (Woodlake, IL, USA) using previously described methods (Das and Boykin, 1977; Boykin et al., 1996) . The intermediate Phase I metabolites (M1, M2, and M3), the active diamidine DB75, and deuterium-labeled DB289 (DB289-d 8 ) (internal standard, IS) were synthesized as described previously (Stephens et al., 2001; Anbazhagan et al., 2003) . HPLC-grade water and acetonitrile were obtained from Fisher Scientific (Pittsburgh, PA). Analyticalgrade ammonium formate, formic acid, magnesium chloride, dimethyl sulfoxide (DMSO), potassium dihydrogen phosphate, disodium hydrogen phosphate anhydrous, NADPH, α-naphthoflavone (α-NF), fluvoxamine, furafylline, coumarin, thio-TEPA, sulfaphenazole, trimethoprim, omeprazole, quinidine, diethyldithiocarbamate (DDC), ketoconazole, troleandomycin (TAO), lauric acid, and 1-aminobenzotriazole (ABT) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). 17-Octadecynoic acid (17-ODYA), HET0016 (N-hydroxy-N'-(4-n-butyl-2-methylphenyl)formamidine), and arachidonic acid (AA) were purchased from Cayman Chemical Co. (Ann Arbor, MI). Ebastine was purchased from Toronto Research Chemicals Inc. (North York, Ontario, Canada). All chemicals were of the highest purity available and used without further purification.
Human Liver Microsomes, Immunoinhibitory Antibodies and Recombinant
Human P450s. Pooled human liver microsomes (n = 50; mixed gender), polyclonal antibody against CYP3A4/5, and pre-immune immunoglobulin (IgG) from rabbit were prepared by XenoTech, LLC (Lenexa, KS). Polyclonal antibody against CYP4F2, raised in rabbits, was purchased from Research Diagnostics, Inc. (Concord, MA) (Source A; 1 mg IgG/mL) or was kindly provided by Dr. Yoshihiko Funae (Osaka City University DMD #10587
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Medical School, Osaka, Japan) (Source B; 40 mg IgG/mL). Polyclonal antibody against CYP2J2 (40 mg IgG/mL) was also a gift from Dr. Funae (Hashizume et al., 2001; Hashizume et al., 2002) . Monoclonal antibody against CYP2J2 (1.1 mg IgG/mL) and a control monoclonal antibody against egg lysozyme were generated in mouse hybridoma cells as described previously (Gelboin et al., 1998; Krausz et al., 2000; Xiao et al., 2004) .
Supersomes™ prepared from baculovirus-infected insect cells expressing human CYP enzymes and NADPH-cytochrome P450 reductase were purchased from BD Biosciences (Woburn, MA). In the case of recombinant CYP2E1, CYP2J2, CYP3A7, CYP4F2, CYP4F3A, CYP4F3B, and CYP4F12, the enzymes were coexpressed with both NADPH- Reactions were initiated with the addition of NADPH (or substrate for incubations with mechanism-based inhibitors) and were carried out at 37°C. DB289, M1, M2, and M3
were dissolved in DMSO. DB75 was dissolved in HPLC-grade water. With the exception of ebastine, all chemical inhibitors were dissolved in methanol. Ebastine was initially dissolved in chloroform at a concentration of 25 mM, which was serially diluted with methanol to concentrations of 2.5 mM, 0.25 mM and 0.025 mM. ice-cold acetonitrile. The mixtures were processed (described above) and analyzed immediately by LC/UV (described below, single determination). Metabolite identification was performed by comparing retention times to those of synthetic standards.
Control incubations were run as described above, except NADPH, microsomal protein or prodrug was absent. Tables 1 and 2 
Incubations with
Results
Phase I Biotransformation of DB289 in Human Liver Microsomes. DB289 was incubated with pooled HLM in the presence of NADPH, and the Phase I metabolites were identified by LC/UV analysis with comparison to synthetic standards.
Representative chromatograms at 0, 5, 15, 30 and 120 min incubation are shown in Fig.   2A . DB289 had a half-life of 12 min in this pooled HLM and was completely consumed by 120 min. M1 appeared to increase over the first 30 min before decreasing over the next 90 min, presumably due to the further conversion of M1 to subsequent metabolites, i.e., M2 and M3 (Fig. 2B) . The major metabolites of DB289 at 120 min were the two oxidative O-demethylation products, M1 and M2. Neither DB289 consumption nor metabolite formation was observed in control incubations without NADPH or HLM (data not shown).
Oxidative O-demethylation of DB289 (M1 formation) is the first step in the biotransformation of DB289 to its active diamidine DB75 (Fig. 1 ). An Eadie-Hofstee plot of the M1 formation rate-substrate concentration data displayed monophasic kinetics over the DB289 concentration range 0.05 -15 µM ( Fig. 3 and Table 1 ).
Initial Reaction Phenotyping Studies for M1 formation in Human Liver
Microsomes (Bjornsson et al., 2003) . Therefore, a panel of recombinant human CYP enzymes was evaluated for their ability to metabolize DB289 (3.0 µM) based on substrate consumption (Fig. 5A ). The percent substrate consumed after 15-min incubation was 82% for CYP1A1, 61% for CYP1A2, 46% for CYP1B1, and 18% for CYP3A4. In addition, CYP2C8, 2D6, 2E1, and 3A5 showed detectable activity towards DB289 (5%, 9%, 7% and 8% consumption, respectively). CYP2A6, 2B6, 2C9
and 2C19 only showed marginal activity (less than 5% consumption). Neither control microsomes obtained from insect cells infected with wild-type baculovirus, nor those infected with baculovirus containing human NADPH-cytochrome P450 reductase and cytochrome b 5 , metabolized DB289 (data not shown).
To evaluate the relative efficiency of CYP enzymes in DB289 metabolism, we determined the kinetics of M1 formation by these recombinant CYP enzymes (Tables 1   and 2 ). Based on in vitro intrinsic or maximal clearance, CYP1A1 was the most efficient at converting DB289 to M1, followed by CYP1A2. CYP1A2 was at least ~300-fold more efficient than CYP3A4, 2D6, 2E1 or 3A5. which renders FMO inactive but has no effect on CYP enzymes, did not impede DB289 metabolism (data not shown). Therefore, the statistically significant relationship between DB289 metabolism and FMO activity was considered a spurious correlation.
Inhibition of human CYP enzyme activities by DB289.
The inhibitory effects of DB289 on hepatic CYP enzymes were investigated using selective marker substrates and pooled HLM. DB289 (3.0 µM) exhibited modest inhibition (~20-25%) towards CYP1A2 and CYP2C9 and minimal to no inhibition towards the remaining CYP enzymes (CYP2A6, 2C19, 2D6, 2E1, 3A and 4A11) (data not shown). In contrast, cytochrome P450-selective chemical inhibitors exhibited potent inhibition (≥ 60%) of the corresponding CYP enzyme activity (data not shown). Fig. 5B . Like CYP1A1 (Fig. 5A ), CYP2J2 and CYP4F2 nearly completely consumed DB289 in 15 min (85% and 98%, respectively). CYP4F3B and CYP4F12 exhibited modest and minimal activity towards DB289, causing 40% and 10% consumption, respectively. CYP4F3A, an alternative splicing variant of CYP4F3B (Christmas et al., 2001) , caused little DB289 consumption up to 120 min. CYP2C18, CYP3A7 and CYP4A11 caused only marginal consumption (less than 5%). It should be noted that the DB289 consumption by recombinant CYP4F2, CYP2J2 and CYP4F3B was NADPH-dependent, and the N-dehydroxylation product, M3 (Fig. 1) , was also detected in the LC/UV analyses. The mechanism for the formation of the N-dehydroxylation product by these recombinant CYP enzymes, which were coexpressed with cytochrome b 5 , remains unclear.
Identification of Other CYP Enzymes
The kinetic parameters of M1 formation were also determined for recombinant CYP2J2, CYP4F2, CYP4F3B and CYP4F12 (Table 1) . The apparent K m and V max values for CYP4F2 and CYP2J2 were comparable to those observed with HLM. The intrinsic clearance value for CYP4F2 was 1.3-, 3.5-and 92-fold greater than that for CYP2J2, CYP4F3B and CYP4F12, respectively.
Immunoinhibition of M1 Formation. To clarify a potential role of CYP2J2 and CYP3A4 in M1 formation by HLM, immunoinhibition experiments were performed with polyclonal antibodies against CYP2J2 or CYP3A4/5. As shown in Fig. 6A , no inhibition was observed at any antibody concentration tested. The same experiment was repeated
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22 with a monoclonal antibody against CYP2J2 at a single concentration (25 µL antibody/0.05 mg HLM), and again, inhibition was not observed (data not shown).
To ascertain the potential role of CYP4Fs in the metabolism of DB289 by HLM, immunoinhibition studies were carried out with polyclonal antibodies raised against CYP4F2 from two independent sources (Source A and Source B as described under
Materials and Methods).
As shown in Fig. 6A , both antibodies against CYP4F2 inhibited M1 formation by HLM in a concentration-dependent manner, with 91% inhibition at the highest concentration tested. Given the extensive amino acid sequence homology (~ 93%) between human CYP4F2 and CYP4F3B (Christmas et al., 2001) , it is reasonable to expect that the polyclonal antibodies against CYP4F2 cross-react with CYP4F3B. Hence, the specificity of the antibody from source A was examined against recombinant CYP4F2, CYP4F3B and CYP2J2 (Fig. 6B ). As expected, this antibody did not inhibit M1
formation by recombinant CYP2J2. However, the same antibody inhibited M1 formation by both recombinant CYP4F2 and CYP4F3B in a concentration-dependent manner, though it appeared to be less inhibitory for CYP4F3B than for CYP4F2. This antibody exhibited less potent inhibition of M1 formation by recombinant CYP4F2 and CYP4F3B than by HLM, possibly due to higher amount of recombinant enzymes used relative to the amount of the enzymes contained in the 0.05 mg of HLM tested (incubation volume and HLM concentration were 0.25 mL and 0.2 mg/mL, respectively). A recent study by Ito et al. showed that their polyclonal antibody raised against CYP4F2 also cross-reacted with these same CYP4F enzymes (Ito et al., 2006) .
Inhibition of M1 Formation by Arachidonic Acid CYP-Mediated Metabolism
Inhibitors and Ebastine. To help determine the contribution of CYP4F2, CYP4F3B
DMD #10587
23 and CYP2J2 to M1 formation by HLM, we examined the inhibitory effects of arachidonic acid (a CYP4F2, CYP4F3B and CYP2J2 substrate) and ebastine (a CYP2J2, CYP4F12
and CYP3A4 substrate). Similarly, the effects of 17-ODYA (a nonselective mechanismbased arachidonic acid ω -hydroxylase and epoxygenase inhibitor) and HET0016 (an arachidonic acid ω -hydroxylase inhibitor) (Zou et al., 1994; Wang et al., 1998; Miyata et al., 2001) were examined (Fig. 7) . The ranges of the concentrations of the inhibitors encompassed the previously reported K i or K m values. In HLM (Fig. 7A ), HET0016 potently inhibited M1 formation by 78% at 0.1 µM and by 95% at 0.5 µM. 17-ODYA inhibited M1 formation by 39% at 1 µM and by 84% at 10 µM. In contrast, as a competitive inhibitor of CYP2J2, ebastine marginally inhibited M1 formation at concentrations up to 10 µM, which is about 8-fold higher than the K m value (1.3 µM)
reported by Hashizume et al. (2002) . Arachidonic acid at 500 µM inhibited M1
formation by 60%, but showed no effect up to 100 µM.
In an attempt to use these inhibitors to determine the relative contribution of CYP4F2 and CYP4F3B to M1 formation in HLM and to confirm that these inhibitors can indeed inhibit M1 formation by individual cytochrome P450s, we investigated the effects of these inhibitors on M1 formation catalyzed by recombinant CYP4F2, CYP4F3B and CYP2J2. CYP4F2 (Fig. 7B ) and CYP4F3B (Fig. 7C ) exhibited similar inhibition profiles by all inhibitors except 17-ODYA, which appeared to activate CYP4F3B at low concentrations (0.2 µM and 1 µM). Such activation was not observed for either CYP4F2 or CYP2J2 (Fig. 7D) . Unexpectedly, HET0016 inhibited recombinant CYP2J2 (by 53% at 0.1 µM), albeit to a much lesser extent than CYP4F2 and CYP4F3B (by 82% and 79%
at 0.02 µM, respectively). Ebastine at 1 µM appeared to be a selective inhibitor of DMD #10587 24 CYP2J2 ( Fig. 7B-D) , but did not inhibit M1 formation by HLM (Fig. 7A ), indicating that CYP2J2 was not a major contributor to M1 formation by HLM. At higher concentrations (> 1 µM), ebastine became non-selective, partially inhibiting both CYP4F2 and CYP4F3B. At a concentration of 100 µM, arachidonic acid potently inhibited M1
formation by recombinant CYP4F2 and CYP4F3B. These results, though not conclusive, suggested that CYP4F2 and CYP4F3B, but not CYP2J2, contribute to M1 formation by HLM.
Differential Inhibition of CYP4F2, CYP4F3B and CYP2J2 by Ketoconazole.
Due to the partial inhibition of M1 formation in pooled HLM by 3 µM ketoconazole (Fig.   4 ), the effects of ketoconazole on recombinant CYP4F2, CYP4F3B and CYP2J2 were investigated. As shown in Fig. 8 , ketoconazole potently inhibited M1 formation by recombinant CYP4F2 and CYP2J2 (87% and 93%, respectively), but had no effect on M1 formation by recombinant CYP4F3B. The partial inhibition (~ 43%) of M1 formation in pooled HLM by 3 µM ketoconazole was consistent with the previous experiment (Fig. 4) . The slight difference in the extent of inhibition was likely due to the lot difference in pooled HLM used.
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Discussion
Several lines of evidence from the current study indicate that in HLM, M1 formation is predominantly and unexpectedly catalyzed by CYP4F enzymes. First, a polyclonal antibody raised against CYP4F2, which inhibited both recombinant CYP4F2 and CYP4F3B (Fig. 6B) , inhibited M1 formation by HLM in a concentration-dependent manner (up to 91%). Second, two arachidonic acid CYP-mediated metabolism inhibitors, HET0016 and 17-ODYA, inhibited M1 formation by HLM in a concentration-dependent manner (Fig. 7A ). Third, with recombinant CYP4F2, the enzyme kinetics of M1
formation were comparable to those observed with HLM (Table 1) . It should be noted that, due to the high plasma protein-binding property of DB289 (Fitzpatrick et al., 2004) , the apparent K m values are likely dependent on the protein concentrations used. In another study with a higher HLM concentration (0.5 mg/mL), the apparent K m value (uncorrected for protein binding) was reported as 2.1 µM.
In support of our conclusion, none of the cytochrome P450-selective chemical inhibitors evaluated (Fig. 4) , with the exceptions of ketoconazole and ABT, substantially inhibited M1 formation by HLM, arguing against roles for CYP1A, CYP2A6, CYP2B6, CYP2C, CYP2D6, CYP2E1, CYP3A and CYP4A. This was further supported, with the exception of the CYP1 enzymes, by the minimal or modest activity of recombinant CYP enzymes towards DB289 consumption (Fig. 5A ) and/or limited intrinsic or maximal clearance values from kinetic studies (Tables 1 and 2 ). Furthermore, CYP3A4/5 did not appear to contribute appreciably to M1 formation by HLM as shown by the lack of inhibition by both TAO (Fig. 4) and a polyclonal antibody against CYP3A4/5 (Fig. 6A ).
However, our preliminary studies indicated that CYP3A4 may play a major role in the conversion of M3 to M4 in the DB289 metabolic activation pathway (Fig. 1) .
Although CYP1A1 and CYP1A2 had the highest intrinsic clearance values among all recombinant enzymes examined, neither appeared to contribute to M1 formation by HLM (Fig. 4) . This was confirmed by polyclonal antibodies against CYP1A1 or CYP1A2, which did not inhibit DB289 metabolism (data not shown). Moreover, because CYP1A1
(and CYP1B1) is predominantly an extrahepatic enzyme (Murray et al., 1997; Paine et al., 1999; Guengerich, 2004; Doshi et al., 2006) , CYP1A1 is unlikely to play a role in M1
formation by HLM.
It is unclear why CYP1A2, which had a high intrinsic clearance towards M1
formation (Table 1 ) and is considered a major hepatic drug-metabolizing enzyme, did not contribute to M1 formation by HLM. DB289 (at 3.0 µM) had a negligible inhibitory effect towards CYP1A2 activity, as well as other major CYP enzymes, with or without a 15-min pre-incubation, using HLM. These results argue against inhibition of CYP1A2 by DB289, or its metabolites, as a potential explanation why CYP1A2 had no contribution to M1 formation by HLM.
DB289 consumption rates did not correlate with marker activities for individual CYP enzymes, including CYP1A2 and CYP3A4. In these studies, individual CYP4F enzymes were not included due to the lack of marker activities. Although leukotriene B 4 (LTB 4 ) ω -hydroxylation could be used as a non-selective marker reaction for the CYP4F subfamily (Kikuta et al., 2002) , the limited variation (4-fold) in DB289 consumption rates (current study), coupled with the limited variation (2-3 fold) in LTB 4 ω -hydroxylation rates observed in a panel of HLM (Drs. Chris Patten and David Stresser,
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27 BD Gentest, personal communication and Jin et al. (1998) ), reduce or eliminate the power of such a correlation analysis.
Although recombinant CYP2J2 could catalyze M1 formation ( Fig. 5B and Table 1) , we concluded that CYP2J2 was not the major enzyme responsible for M1 formation by HLM due to the lack of inhibition by antibodies against CYP2J2 (Fig. 6A) and by ebastine, a competitive inhibitor of CYP2J2 (Fig. 7A) . Human CYP2J2 is predominantly expressed in extrahepatic tissues, such as the small intestine and heart (Wu et al., 1996; Scarborough et al., 1999) . Therefore, like CYP1A1 and CYP1B1, CYP2J2 may be involved in the extrahepatic metabolism of DB289. Another study by Hashizume et al. (2002) demonstrated that CYP2J2 is the predominant ebastine hydroxylase in human intestinal microsomes. This raises the possibility that DB289 could undergo significant first-pass metabolism by CYP2J2 in human intestine after oral administration.
Over the last decade, a number of studies have shown that CYP4F2 and CYP4F3B
are constitutively expressed at relatively high levels in human liver. Different methods of quantification were used, including immunoquantitation (Jin et al., 1998) and enzymespecific quantitative RT-PCR (Christmas et al., 2001 ). Caution should be taken when considering the expression levels of CYP4F2 and CYP4F3B, due to the 93% amino acid sequence identity. If an antibody against CYP4F2 or CYP4F3B is used for the quantification of these enzymes, it should be presumed that final measurements are the sum of both enzymes, unless the antibody has been explicitly tested for its specificity Members of the CYP4F subfamily are important enzymes involved in the biotransformation of endogenous compounds (e.g., arachidonic acid, LTB 4 ) and are involved in the regulation of numerous physiological functions, such as inflammation and vasoconstriction (Jin et al., 1998; Sarkis et al., 2004; Kroetz and Xu, 2005) . Although the role of CYP4F enzymes in drug disposition is largely unknown, Zimmerlin and Patten (2000) reported that the promising immunomodulatory agent, FTY720 [2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol], is eliminated predominantly by CYP4F-mediated ω -hydroxylation of the aliphatic chain. FTY720 ω -hydroxylation kinetics in HLM exhibited a V max value comparable to that obtained for DB289 (1850 versus 3770 pmol/min/mg protein). However, the apparent K m value for FTY720 was much higher than that for DB289 O-demethylation (180 µM versus 0.5 µM), presumably due to structural differences between the two drugs.
In our attempt to determine the relative contributions of CYP4F2 and CYP4F3B to M1 formation by HLM, ketoconazole was shown to selectively inhibited M1 formation by recombinant CYP4F2, but had little effect on M1 formation by recombinant CYP4F3B (Fig. 8) . This same concentration of ketoconazole only partially inhibited M1
29 formation by HLM, suggesting that CYP4F2 and CYP4F3B both contribute to M1
formation. Ketoconazole may provide a tool to distinguish these two closely related enzymes if the contribution from CYP3A4/5 can be established by other means (e.g., TAO and immunoinhibition). Based on these results, CYP4F3B could be as important as CYP4F2 for M1 formation by HLM. Another member of the CYP4F subfamily, CYP4F11, has also been shown to be expressed primarily in human liver (Cui et al., 2000) . In addition, CYP4F8 was identified in human seminal vesicles, but limited mRNA expression was detected in human liver (Bylund et al., 1999) . Potential contributions to M1 formation in HLM by these CYPs remain uncharacterized due to the paucity of tools available to evaluate these enzymes.
DB289 biotransformation to its active form, DB75, consists of three O-demethylation
reactions, i.e., M1 and M2 formation, and conversion of M3 to M4 (Fig. 1) . It is not known whether all of these reactions are mediated by the same enzyme(s) in HLM.
Preliminary data indicate that CYP4F enzymes are capable of catalyzing the Odemethylation of M1 to form M2, and CYP3A4 appears to efficiently catalyze the Odemethlyation of M3 to form M4. Investigation to elucidate the complete pathway of DB289 biotransformation in HLM is currently underway.
In conclusion, DB289 O-demethylation to M1 in HLM appears to be mediated primarily by CYP4F enzymes, including CYP4F2 and CYP4F3B. Thus, in human liver, members of the CYP4F subfamily not only metabolize endogenous compounds, such as arachidonic acid and eicosanoids, but also xenobiotics. Their potential as drugmetabolizing enzymes remains to be fully understood. 
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